Oramed Pharmaceuticals Inc.
ORMP
$3.65
$0.010.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 110.00M | 64.05M | 43.85M | -24.16M | -28.24M |
| Total Depreciation and Amortization | 121.00K | 121.00K | 122.00K | 143.00K | 167.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -134.07M | -79.32M | -59.94M | 10.52M | 15.36M |
| Change in Net Operating Assets | 15.40M | 6.00M | 5.38M | -2.57M | 2.25M |
| Cash from Operations | -8.54M | -9.15M | -10.59M | -16.07M | -10.46M |
| Capital Expenditure | -11.00K | -9.00K | -18.00K | -23.00K | -19.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -37.65M | 5.45M | 22.57M | -50.05M | 99.45M |
| Cash from Investing | -37.66M | 5.44M | 22.55M | -50.07M | 99.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | 0.00 | -30.55M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -4.74M | -4.74M | -1.93M | -2.86M | -2.49M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -10.36M | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -15.11M | -4.74M | -1.93M | -2.86M | -33.04M |
| Foreign Exchange rate Adjustments | -7.00K | -30.00K | 41.00K | 40.00K | -4.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.31M | -8.47M | 10.08M | -68.96M | 55.94M |